This collection
is approved through 5/00. FDA will resubmit this package on or
before the date of the publication of the final rule. In developing
the final rule, FDA will address all comments received on the
information collection requirments contained in both the rule and
the guidance. In particular, FDA shall address concerns raised
concerning the burden of and the need for the collection of
information on manufacturing changes, including whether the changes
adequately address the statutory changes under FDAMA.
Inventory as of this Action
Requested
Previously Approved
05/31/2000
05/31/2000
11,913
0
0
641,705
0
0
0
0
0
Guidance to assist applicants in
reporting to FDA changes to an approved NDA or ANDA.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.